Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies

Bone Marrow Transplantation

Volumn 43, Issue 6, 2009, Pages 469-476

  Horn, B ^a   Soni, S ^b   Khan, S ^c   Petrovic, A ^d   Breslin, N ^b   Cowan, M ^a   Pelle Day, G ^a   Cooperstein, E ^a   Baxter Lowe, L A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KOSAIR CHILDREN'S HOSPITAL   (United States)

^c MAYO CLINIC   (United States)

^d JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CHILD; CHIMERA; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL;

ADOLESCENT; ANTIGENS, CD3; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFANT; RECURRENCE; RISK; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 63949085142     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.339     Document Type: Article

References (23)

1. Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487-495.
2. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplantation 2004; 33: 815-821.
3. Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P et al. Prevention of relapse in pediatric patients with acute leukemia and MDS after allogeneic SCT: A single center experience of 12 children. Leukemia 1999; 13: 2079-2086.
4. Gorczynska E, Turkiewicz D, Toporski J, Kalwak K, Rybka B, Ryczan R et al. Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: A report of 14 children. Bone Marrow Transplant 2004; 33: 211-217.
5. Barrios M, Jimenez-Velasco A, Roman-Gomez J, Madrigal ME, Castillejo JA, Torres A et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica 2003; 88: 801-810.
6. Bader P, Stoll K, Huber S, Geiselhart A, Handgretinger R, Niemeyer C et al. Characterization of lineage-specific chimaerism in patients with acute leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. Br J Hematol 2000; 108: 761-768.
7. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696-1706.
8. Bader P, Niemeyer C, Willasch A, Kreyenberg H, Strahm B, Kremens B et al. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy. Br J Hematol 2005; 128: 649-658.
9. Yoshimi A, Niemeyer C, Bohmer V, Duffner U, Strahm B, Kreyenberg H et al. Chimerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukemia. Br J Hematol 2005; 129: 542-549.
10. Huisman C, Weger RA, de Vries L, Tilanus MGJ, Verdonck LF. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 2007; 39: 285-291.
11. Mattson J, Uzunel M, Tammik L, Aschan J, Ringden O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15 1976-1985.
12. Gardiner N, Lawler M, O'Riordan JM, Duggan C, De Arce M, McCann SR. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukemia. Bone Marrow transplant 1998; 21: 711-719.
13. Zetterquist H, Mattsson J, Uzunel M, Nasman-Bjork I, Svenberg P, Tammik L et al. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplant 2000; 25: 843-851.
14. Miura Y, Tanaka J, Toubai T, Tsutsumi Y, Kato N, Hirate D et al. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and nonmyeloablative stem cell transplantation. Bone Marrow Transplant 2006; 37: 837-843.
15. Zeiser R, Spyridonidis A, Wasch R, Ihorst G, Grullich C, Bertz H et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 2005; 19: 814-821.
16. Scharf S, Smith A, Hansen J, McFarland C, Erlich H. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995; 85: 1954-1963.
17. Przepiorka D, Wiesdorf D, Martini P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
18. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man: Long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
19. Lutz C, Massenkeil G, Nagy M, Neuburger S, Tamm I, Rosen O et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 805-812.
20. Lim ZY, Pearce L, Ingram W, Ho AYL, Mufti GJ, Pagliuca A. Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative. Bone Marrow Transplant 2008; 41: 587-588.
21. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E et al Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005; 108: 774-782.
22. Koldehoff M, Steckel N, Hlinka M, Beelen D, Elmaagacli A. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and y-chromosome specific sequences. Am J Hematol 2006; 81: 735-746.
23. Willasch A, Schneider G, Reincke BS, Shayegi N, Kreyenberg H, Kuci S et al. Sequence polymorphism systems for quantitative real-time polymerase chain reaction to characterize hematopoietic chimerism - High informativity and sensitivity as well as excellent reproducibility and precision of measurement. Lab Hematol 2007; 13: 73-84.